New Zealand

Home / Species & Products / Dogs / Clavulox Palatable Tablets

Clavulox Palatable Tablets

Clavulox Palatable Tablets is a broad spectrum antibiotic for the treatment of bacterial infections sensitive to Clavulanic Acid and Amoxycillin in calves, dogs and cats.

Expand All
  • Approved uses/Indications

    50mg and 250mg

    Oral treatment of bacterial infections caused by susceptible organisms in cats and dogs. Clinically, Clavulox has been shown to be effective in treating a wide range of diseases of cats and dogs including: skin disease (including deep and superficial pyodermas), urinary tract infection, respiratory disease (involving upper and lower respiratory tract), and enteritis.

    500mg

    Oral treatment of bacterial infections caused by susceptible organisms in calves and dogs. These include enteritis, respiratory tract infections, and skin infections in dogs.

  • Key Features
    1. Clavulox Palatable Tablets are the most widely prescribed oral antibiotic for companion animals in New Zealand1.
    2. Clavulox is a reliable broad spectrum treatment and has an excellent safety profile.
    3. Clavulox has been specifically designed for animal use. The novel formulation of Clavulox increases the high cure rates achieved with amoxicillin alone.
    4. Easy to administer.
    5. Excellent absorption and penetration.
    6. Clavulox has activity against both gram positive and gram negative aerobes and anaerobes.
    7. Clavulanic acid binds to the beta - lactamase enzyme allowing the amoxycillin to kill the bacteria.
    8. Clavulox has proven success against mixed bacterial infections in most body tissues.
    9. After many years of extensive use in animals, bacterial susceptibility remains high2

    Resistance to many antibiotics is caused by enzymes that destroy the antibiotic before it can act on the bacteria. The clavulanate in Clavulox counteracts this defence mechanism by inactivating the ß-lactamases, thus rendering the organisms sensitive to the rapid bactericidal effect of amoxycillin at concentrations readily attainable in the body. In vitro, Clavulox is active against a wide range of clinically important bacteria including: Gram-positive: Staphylococcus spp. (including ß-lactamase producing strains), Corynebacterium spp, Streptococcus spp. Gram-negative: Escherichia coli (including ß-lactamase producing strains), Salmonella spp. (including ß-lactamase producing strains), Bordetella bronchiseptica, Pasteurella, Proteus mirabilis and other sensitive strains, and Klebsiella. Clavulox is not indicated for cases involving Pseudomonas spp.

  • Packaging

    50mg

    A pink, scored tablet containing 40mg amoxycillin and 10mg clavulanic acid in a palatable base. 100 tablets per carton.

    250mg

    A pink, scored tablet containing 200mg amoxycillin and 50mg clavulanic acid in a palatable base. 250 tablets per carton.

    500mg

    A pink, scored tablet containing 400mg amoxycillin and 100mg clavulanic acid in a palatable base. 100 tablets per carton.

    Store below 25°C (air conditioning) in a dry place.

  • Dosage & Administration

    For oral administration only. Clavulox Palatable Tablets are often accepted from the hand even by sick cats and dogs. Alternatively, the tablets may be crushed and added to a little food.

    50mg

    The standard dose is 12.5mg/kg (1 tablet/4kg) bodyweight twice daily. Refractory cases may require doubling the dose to 25mg/kg twice daily. Treatment should be continued for 5–7 days or for 48 hours after all symptoms have subsided. In chronic or refractory cases, and/or where there is considerable tissue damage, a longer course may be required to allow sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:

    Chronic skin disease

    10–20 days

    Chronic cystitis

    10–28 days

    Respiratory disease

    8–10 days

     

    250mg

    The standard dose is 12.5mg/kg (1 tablet/20 kg) bodyweight twice daily. Refractory cases may require doubling the dose to 25mg/kg twice daily. Treatment should be continued for 5–7 days or for 48 hours after all symptoms have subsided. In chronic or refractory cases, and/or where there is considerable tissue damage, a longer course may be required to allow sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:

    Chronic skin disease

    10–20 days

    Chronic cystitis

    10–28 days

    Respiratory disease

    8–10 days

     

    500mg

    CALVES: The recommended dose rate is 6.25–12.5mg/kg (1 tablet per 40–80kg) bodyweight twice daily. Use the higher dose rate for the initial dose and for severely affected calves. Treatment should be continued until 12 hours after all symptoms have subsided. Example: a 40kg calf requires one 500mg tablet initially, followed by half a 500mg tablet twice daily. In severe cases, one 500mg tablet should be given twice daily. Any variation by the prescribing veterinarian to the approved dose, frequency, duration, route or target species may result in a need to extend the approved withholding period.

    DOGS: The standard dose is 12.5mg/kg (1 tablet/40kg) twice daily. Refractory cases may require doubling the dose to 25mg/kg twice daily. Treatment should be continued for 5–7 days or for 48 hours after all symptoms have subsided. In chronic or refractory cases, and/or where there is considerable tissue damage, a longer course may be required to allow sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested as guidelines:

    Chronic skin disease

    10–20 days

    Chronic cystitis

    10–28 days

    Respiratory disease

    8–10 days

     

  • Precautions

    Do not administer to small herbivores (eg. guinea pigs) or animals with a history of allergic reactions to penicillins.

    Penicillins may cause hypersensitivity (allergy) following inhalation, ingestion or skin contact. Do not handle the product if you know you are sensitised to, or if you have been advised not to work with, such preparations. This material may affect the gastrointestinal system if ingested repeatedly in high doses.

    Contains amoxycillin, a semi-synthetic penicillin, and has the potential for producing hypersensitivity reactions. If a hypersensitivity reaction occurs, administer adrenaline and/or corticosteroids.

    Meat Withholding time: Not for use in bobby calves. Calves producing meat and offal for human consumption must not be slaughtered within 4 days of last treatment. Any variation by the prescribing veterinarian to the approved dose, frequency, duration, route, disease or target species may result in the need to extend the approved withholding period.

    Prescription Animal Remedy. Keep out of reach of children. For animal treatment only.

  • Mandatories

    Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. CLAVULOX is a registered trade mark of GlaxoSmithKline NZ Ltd. ACVM Registration No. A8139 & A8140. RVM; Available only under Veterinary Authorisation.

    References:

    1. Baron Strategic Services, NZ Animal Health Market Audit, May 2008.
    2. Helen Hefferman, Scientist, ESR: Surveillance of Antimicrobial Resistance Among Animal Pathogens In New Zealand, 2001.
  • Contact Information

    For technical enquiries please phone Zoetis Technical Services on 0800 650 277.